The Effect of Mesenchymal Stem Cells in Systemic Lupus Erythematosus: A Systematic Review Nurhasan Agung Prabowo, Arief Nurudhin, Desy Puspa Putri, and Yulyani Werdiningsih
1.Faculty of Medicine, Universitas Sebelas Maret, Ir Sutami Street No 36, Kentingan, Jebres, Surakarta, Indonesia, 57126
2.Universitas Sebelas Maret Hospital, Ahmad Yani Street No 200, Kartasura, Sukoharjo, Indonesia, 57161
3.Doctoral Degree of Medical Science Program, Faculty of Medicine, Universitas Sebelas Maret, Ir Sutami Street No 6, Kentingan, Jebres, Surakarta, 57126
Abstract
SLE is an autoimmune illness affecting various organs and tissues. MSCs (mesenchymal stem cells) are a promising treatment option for autoimmune and haematological diseases. The effectiveness and mechanisms of MSC treatment for SLE will be summarized in this review. Therefore, this paper aims to review mesenchymal stem cells in SLE. We looked through Pubmed, Cochrane, and Scopus to find peer-reviewed studies that looked at how mesenchymal stem cells affect SLE. The research included in this review was a study from 2000 to 2022, a randomized control trial using intervention mesenchymal stem cells, the full text of the article can be obtained, and the patient^s age is over 18 years. Three reviewers independently extracted data on relevant clinical outcomes, trial characteristics, and patient characteristics and used the Cochrane Risk of Bias Assessment Tool. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation. In SLE patients, MSC treatment can lower anti-dsDNA, antinuclear antigen (ANA), proteinuria, and serum creatinine. To ameliorate the lesions in SLE, MSCs can block inflammatory factors like MCP-1 and HMGB-1, as well as inflammation-related signalling pathways including the NF-B, JAK/STAT, and Akt/GSK3 signalling pathways
